ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML

Bookmark and Share
Published: 20 Jun 2019
Views: 740
Rating:
Save
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

Prof Alexander Perl speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the updated results from the AMIRAL study looking at the use of gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia (AML).

He explains that patients were randomised 2:1 to either single agent gilteritinib or investigator's choice standard chemotherapy.

Prof Perl explains that the gilteritinib arm showed higher response rates and also improved survival.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.